Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ziv-aflibercept by Regeneron Pharmaceuticals for Metastatic Uveal Melanoma: Likelihood of Approval
Ziv-aflibercept is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...